Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Alcohol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 6/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 0.48 |
| ▸ | PARP1 | P09874 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.46 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.46 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56532 | 0.88 | PARP10 (0.74) | PARP10CYP3A4LMNAPARP4PARP1 | |
| Terephthalamide SCHEMBL437011 | 0.88 | PARP10 (0.74) | PARP10CYP3A4LMNAPARP4PARP1 | |
| SCHEMBL7642130 | 0.88 | PARP10 (0.74) | PARP10CYP3A4LMNAPARP4PARP1 | |
| Hydrochloric Acid SCHEMBL4408462 | 0.85 | PARP10 (0.71) | PARP10CYP3A4LMNAPARP4PARP1 | |
| Water SCHEMBL6343332 | 0.85 | PARP10 (0.71) | PARP10CYP3A4LMNAPARP4PARP1 | |
| Ethylenediamine SCHEMBL9419697 | 0.84 | PARP10 (0.63) | PARP10CYP3A4LMNACYP1A2MAOA | |
| Acetic Acid SCHEMBL29098941 | 0.84 | PARP10 (0.63) | PARP10CYP3A4LMNACYP1A2MAOA | |
| Benzene SCHEMBL28558933 | 0.83 | PARP10 (0.68) | PARP10CYP3A4CYP1A2PARP4PARP1 | |
| Benzene SCHEMBL6865184 | 0.83 | PARP10 (0.68) | PARP10CYP3A4CYP1A2PARP4PARP1 | |
| SCHEMBL3948590 | 0.82 | PARP10 (0.61) | PARP10CYP3A4LMNACYP1A2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116496452-A | Low-sensitivity super-early-strength polycarboxylate superplasticizer and preparation method thereof | 厦门路桥翔通建材科技有限公司 | 2023-07-28 | — | — | CN | claimed |
| CN-116874266-B | Detachable acoustic insulation board and manufacturing method thereof | 宝都国际新材料有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-116874266-A | Detachable acoustic insulation board and manufacturing method thereof | 宝都国际新材料有限公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-116496452-A | Low-sensitivity super-early-strength polycarboxylate superplasticizer and preparation method thereof | 厦门路桥翔通建材科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-10738016-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190055203-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2019-02-21 | — | — | US | disclosed |
| US-10106507-B2 | Potent dual BRD4-kinase inhibitors as cancer therapeutics | H. Lee Moffitt Cancer Center and Research Insitute, Inc. (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180290984-A1 | BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-10-11 | — | — | US | disclosed |
| US-20170226065-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-08-10 | — | — | US | disclosed |
| WO-2017066428-A1 | BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2016022460-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738016-B2 | BRD4-kinase inhibitors as cancer therapeutics | BRD4, BICRA, BRDT | PARP10 95/4885CYP3A4 2417/4885LMNA 3929/4885 |
| US-20180290984-A1 | BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | BRD4, BICRA, BRDT | PARP10 95/4885CYP3A4 2417/4885LMNA 3929/4885 |
| US-10106507-B2 | Potent dual BRD4-kinase inhibitors as cancer therapeutics | BRD4, BICRA, BRDT | PARP10 71/4885CYP3A4 4200/4885LMNA 3223/4885 |
| US-20190055203-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | BRD4, BICRA, BRDT | PARP10 71/4885CYP3A4 4200/4885LMNA 3223/4885 |
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | BRD4, BICRA, BRDT | PARP10 95/4885CYP3A4 2417/4885LMNA 3929/4885 |
| US-20170226065-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | BRD4, BICRA, BRDT | PARP10 71/4885CYP3A4 4200/4885LMNA 3223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.